ABT-418

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529906

CAS#: 147402-53-7

Description: ABT-418 is a nicotinic acetylcholine receptor (nAchR) agonist potentially for the treatment of attention deficit disorder.


Chemical Structure

img
ABT-418
CAS# 147402-53-7

Theoretical Analysis

MedKoo Cat#: 529906
Name: ABT-418
CAS#: 147402-53-7
Chemical Formula: C9H14N2O
Exact Mass: 166.11
Molecular Weight: 166.22
Elemental Analysis: C, 65.03; H, 8.49; N, 16.85; O, 9.62

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: A-81418; ABT-418; A81418; ABT418; A 81418; ABT 418;

IUPAC/Chemical Name: Isoxazole, 3-methyl-5-((2S)-1-methyl-2-pyrrolidinyl)-

InChi Key: ILLGYRJAYAAAEW-QMMMGPOBSA-N

InChi Code: InChI=1S/C9H14N2O/c1-7-6-9(12-10-7)8-4-3-5-11(8)2/h6,8H,3-5H2,1-2H3/t8-/m0/s1

SMILES Code: CN1[C@H](C2=CC(C)=NO2)CCC1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 166.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Guo T, Yang C, Guo L, Liu K. A comparative study of the effects of ABT-418 and methylphenidate on spatial memory in an animal model of ADHD. Neurosci Lett. 2012 Oct 18;528(1):11-5. doi: 10.1016/j.neulet.2012.08.068. PubMed PMID: 22985505.

2: Dallanoce C, Magrone P, Matera C, Lo Presti L, De Amici M, Riganti L, Clementi F, Gotti C, De Micheli C. Synthesis of novel chiral Δ2-isoxazoline derivatives related to ABT-418 and estimation of their affinity at neuronal nicotinic acetylcholine receptor subtypes. Eur J Med Chem. 2010 Dec;45(12):5594-601. doi: 10.1016/j.ejmech.2010.09.009. PubMed PMID: 20932609.

3: Kenney JW, Wilkinson DS, Gould TJ. The enhancement of contextual fear conditioning by ABT-418. Behav Pharmacol. 2010 May;21(3):246-9. doi: 10.1097/FBP.0b013e32833a5b9d. PubMed PMID: 20400893; PubMed Central PMCID: PMC3042125.

4: Reichel CM, Murray JE, Barr JD, Bevins RA. Extinction with varenicline and nornicotine, but not ABT-418, weakens conditioned responding evoked by the interoceptive stimulus effects of nicotine. Neuropharmacology. 2010 Jun;58(8):1237-45. doi: 10.1016/j.neuropharm.2010.03.005. PubMed PMID: 20302882; PubMed Central PMCID: PMC2881947.

5: Takechi K, Suemaru K, Kiyoi T, Tanaka A, Araki H. The α4β2 nicotinic acetylcholine receptor modulates autism-like behavioral and motor abnormalities in pentylenetetrazol-kindled mice. Eur J Pharmacol. 2016 Mar 15;775:57-66. doi: 10.1016/j.ejphar.2016.02.021. PubMed PMID: 26868186.

6: Sihver W, Fasth KJ, Ogren M, Bivehed H, Bergström M, Nordberg A, Watanabe Y, Långström B. In vitro evaluation of 11C-labeled (S)-nicotine, (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole, and (R,S)-1-methyl-2-(3-pyridyl)azetidine as nicotinic receptor ligands for positron emission tomography studies. J Neurochem. 1998 Oct;71(4):1750-60. PubMed PMID: 9751211.

7: Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT, et al. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther. 1994 Jul;270(1):319-28. PubMed PMID: 7913497.

8: Young JW, Meves JM, Geyer MA. Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test. Behav Brain Res. 2013 Mar 1;240:119-33. doi: 10.1016/j.bbr.2012.11.028. PubMed PMID: 23201359; PubMed Central PMCID: PMC3538919.

9: Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS, et al. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization. J Pharmacol Exp Ther. 1994 Jul;270(1):310-8. PubMed PMID: 7518514.

10: Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, Soriano J, Fine C, Abrams A, Rater M, Polisner D. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1999 Dec;156(12):1931-7. PubMed PMID: 10588407.

11: Sihver W, Fasth KJ, Ogren M, Lundqvist H, Bergström M, Watanabe Y, Långström B, Nordberg A. In vivo positron emission tomography studies on the novel nicotinic receptor agonist [11C]MPA compared with [11C]ABT-418 and (S)(-)[11C]nicotine in rhesus monkeys. Nucl Med Biol. 1999 Aug;26(6):633-40. PubMed PMID: 10587101.

12: Valette H, Bottlaender M, Dollé F, Dolci L, Syrota A, Crouzel C. An attempt to visualize baboon brain nicotinic receptors with N-[11C]ABT-418 and N-[11C]methyl-cytisine. Nucl Med Commun. 1997 Feb;18(2):164-8. PubMed PMID: 9076773.

13: McGaughy J, Decker MW, Sarter M. Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats. Psychopharmacology (Berl). 1999 May;144(2):175-82. PubMed PMID: 10394999.

14: Prendergast MA, Jackson WJ, Terry AV Jr, Decker MW, Arneric SP, Buccafusco JJ. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology (Berl). 1998 Mar;136(1):50-8. PubMed PMID: 9537682.

15: Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology (Berl). 1999 Mar;142(4):334-42. PubMed PMID: 10229057.

16: Anderson DJ, Williams M, Pauly JR, Raszkiewicz JL, Campbell JE, Rotert G, Surber B, Thomas SB, Wasicak J, Arneric SP, et al. Characterization of [3H]ABT-418: a novel cholinergic channel ligand. J Pharmacol Exp Ther. 1995 Jun;273(3):1434-41. PubMed PMID: 7791118.

17: Prendergast MA, Terry AV Jr, Jackson WJ, Marsh KC, Decker MW, Arneric SP, Buccafusco JJ. Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418. Psychopharmacology (Berl). 1997 Apr;130(3):276-84. PubMed PMID: 9151363.

18: Papke RL, Thinschmidt JS, Moulton BA, Meyer EM, Poirier A. Activation and inhibition of rat neuronal nicotinic receptors by ABT-418. Br J Pharmacol. 1997 Feb;120(3):429-38. PubMed PMID: 9031746; PubMed Central PMCID: PMC1564486.

19: Brioni JD, Kim DJ, Brodie MS, Decker MW, Arneric SP. ABT-418: discriminative stimulus properties and effect on ventral tegmental cell activity. Psychopharmacology (Berl). 1995 Jun;119(4):368-75. PubMed PMID: 7480515.

20: Donnelly-Roberts DL, Xue IC, Arneric SP, Sullivan JP. In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418. Brain Res. 1996 May 6;719(1-2):36-44. PubMed PMID: 8782861.